This difference may be explained in part by super-pathological A3A expression levels in the HAP1-TK-M9 system (at least 5-fold higher than levels in breast tumors or cell lines) and in part by the higher intrinsic activity of this enzyme in comparison to A3B. The gene discussed is APOBEC3A; the disease is breast neoplasm.